Zoetis Receives FDA Approval for Parasite Prevention Drug for Dogs - Nasdaq
Zoetis Receives FDA Approval for Parasite Prevention Drug for Dogs - Nasdaq |
Zoetis Receives FDA Approval for Parasite Prevention Drug for Dogs - Nasdaq Posted: 27 Feb 2020 01:14 PM PST Zoetis (NYSE: ZTS) announced on Thursday that its new all-in-one parasite protection treatment for dogs had received approval from the U.S. Food and Drug Administration. Simparica Trio is a once-per-month chewable tablet that protects dogs from three prominent types of parasites common to canines, heartworm disease, fleas, and ticks. Clinical studies testing Simparica Trio demonstrated 100% efficacy in preventing the onset of heartworm disease, as well as a 98.9% effectiveness in fighting existing tick infestations in dogs. Simparica Trio also has a 100% efficacy in killing fleas eight hours after the initial treatment. While the treatment isn't as certain for other types of parasites, tests have shown that it's also reasonably reliable in eliminating roundworms (99% effective) and hookworms (94% effective). ![]() Image source: Getty Images. "Simparica Trio makes it easier for dog owners to follow their veterinarians' recommendations for parasite protection because it covers the most common parasites in just one convenient chewable," said Chris Adolph, a senior veterinary specialist at Zoetis. Further detailsZoetis is the world's largest producer of veterinary medicines and pharmaceutical products for animals. Over the past 18 months, it received a number of additional approvals for parasitic prevention products to help cats and dogs. One of them is a treatment called ProHeart, which was approved on July 19 as a once-per-year injection to prevent heartworm disease in dogs. Before that, Zoetis received approval for Revolution Plus in November 2018, a 6-in-1 topical parasite protection treatment for cats and kittens. 10 stocks we like better than Zoetis David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Zoetis wasn't one of them! That's right -- they think these 10 stocks are even better buys. *Stock Advisor returns as of December 1, 2019 Mark Prvulovic has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. |
You are subscribed to email updates from "parasitic diseases examples" - Google News. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States |
Comments
Post a Comment